

DUR Board Meeting Minutes Draft

Name of Meeting Drug Utilization Review Board

Date of Meeting Thursday, January 7, 2010

Length of Meeting 2:08 PM – 3:11 PM

Location of Meeting DMAS 7th Floor Conference Room

Members Present:

Geneva Briggs, PharmD
Bill Rock, PharmD
Avtar Dhillon, MD
Jamie Haight, RPh
Randy Ferrance, MD
Jane Settle, NP
Jason Lyman, MD
Renita Driver, PharmD

Members Absent: Cynthia Fagan, FNP; Michele Thomas, PharmD; Sandra Dawson, R.Ph. MSHA; Jonathan Evans, MD, MPH)

DMAS Attendees:

Bryan Tomlinson, Health Care Services Division Director
Keith Hayashi, Pharmacist
Rachel Cain, PharmD
Donna Francioni-Proffitt, Pharmacy Program Manager
Tyrone Wall, Compliance Specialist
Scott Cannady, Senior Health Policy Analyst

First Health Services Contractor: Donna Johnson, RPh., Debbie Moody, RPh

Visitors:

Dave Croft, BMS
Tim Carr, BMS
Joe West, B-I
Brandon Morris, Lilly
Paul Puroy, Amgien
Jim Farrell, Auxilium
Susan Matthews, Med Immune
Matt Sheffield, B-I
Rob Berringer, ACS

Call to Order and Introductions

Chair Geneva Briggs called the meeting to order and asked guests to introduce themselves and announce their affiliation.

Rachel Cain and Donna Johnson presented the results of the September 2009 RetroDUR intervention involving the use of atypical antipsychotics in children less than 6 years old. Intervention packets were sent to prescribers of these medications in this pediatric population. The packet included an informational cover letter, their patient's pharmacy and medical claims profile and a brief questionnaire to be completed and returned to First Health. Dr. Cain and Ms. Johnson followed up by telephone with the prescribers who did not return the questionnaire. The Board reviewed and discussed the findings of this survey. The following options were discussed regarding the tracking and monitoring of atypical antipsychotic usage in this population:

- Require the prescriber to submit a prior authorization request for atypical antipsychotics in children under six years of age;
- Monitor all new recipients under the age of 6 years old prescribed atypical antipsychotic medications; and
- Monitor prescribers to ensure that the patients are being monitored for metabolic changes by ordering blood glucose and lipid level testing.

The Board expressed concern about the safety of these medications in all patients, not just children. They requested that a RetroDUR review be performed to look at all patients on atypical antipsychotics to determine if patients are receiving regular blood glucose and lipid testing no less than once every 12 months.

The Board also requested that a report of any new children recently prescribed an atypical antipsychotic be presented at each DUR Board meeting. The report should include the patient's diagnosis, current medications, past medications, pertinent lab tests and the prescriber specialty if available.

Other Business: none

The meeting was adjourned at 3:11 P.M.